Device Trial Radar · NCT07643467
Fluorescent Probe for Assessment of Renal Elimination
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
May 31, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Aaron CookAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Accurate measures of kidney function is important for precision dosing of many medications. The current methods of determining kidney function largely hinge on the use of equations that use common laboratory values such as serum creatinine \& static variables like age \& weight. These are helpful for trending over time, but often are inaccurate during times of medical illness. Other more accurate methods of measuring kidney function include urine collection, although this is not commonly used because of various reasons that make the collection inconvenient or unreliable. The new transdermal glomerular filtration (tGFR) device permits accurate, real-time evaluation of kidney function. This novel method has not been rigorously compared with urine collection \& other methods of determining kidney function in hospitalized patients. The goal of the study is to compare tGFR with other accepted methods of determining kidney function.
Conditions
- Augmented Renal Clearance
- Critical Illness
Interventions
RelmapirazinDrug
IV push of relmapirazin (Lumitrace) prior to use of the tGFR device
IohexolDrug
Small IV push bolus of iohexol as a probe for renal function will be administered prior to use of the tGFR device.
Medibeacon tGFR monitorDevice
The tGFR monitor will be applied to the patient after relmapirazin bolus for measurement of GFR.
Urine creatinine clearance collectionDiagnostic test
8-hour urine creatinine clearance collection will be performed during the study period to compare to tGFR \& other renal function measures.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Transdermal Glomerular Filtration Rate (tGFR) Monitoring AccuracyTime frame: 8 Hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UKHealthCare/University of Kentucky
Lexington, Kentucky · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.